title: Metoprolol and diltiazem ameliorate ziprasidone-induced prolonged corrected QT interval in rats.
abstract: Ziprasidone, an atypical antipsychotic agent, has been shown to increase the corrected QT (QTc) interval in some patients. The aim of this study was to reveal the effects of metoprolol and diltiazem on ziprasidone drug-induced prolonged QTc interval. A total of 24 rats were equally divided into the following four groups: the first group was used as the control and received 1 mL/kg saline; 3 mg/kg ziprasidone and saline were administered to the second group; 3 mg/kg ziprasidone and 1 mg/kg metoprolol were administered to the third group and 3 mg/kg ziprasidone and 2 mg/kg diltiazem were administered to the fourth group. Two hours following application of the drugs, the QTc was calculated by performing electrocardiography in derivation (D)I. The duration of QTc interval was compared among the four groups. The mean QTc intervals were significantly increased in the third and fourth groups compared with the second group (p < 0.0005 and p < 0.0001, respectively). The study demonstrated the effectiveness of metoprolol and diltiazem in the prevention of ziprasidone-induced elongation in the QTc interval. Both metoprolol and diltiazem may be considered in the prophylactic therapy of high-risk patients who are using ziprasidone.
authors.affiliation: Department of Physiology, Faculty of Medicine, Ege University, Izmir, Turkey.
authors.forename: Oytun
authors.initials: O
authors.lastname: Erbas
authors.affiliation: Department of Neurology, Faculty of Medicine, Mugla University, Mugla, Turkey mustafayilmaz@mu.edu.tr.
authors.forename: Mustafa
authors.initials: M
authors.lastname: Yilmaz
mesh_terms: D058671:Adrenergic beta-1 Receptor Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000758:Anesthesia; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000008:administration & dosage / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors*; D002121:Calcium Channel Blockers / Q000008:administration & dosage / Q000627:therapeutic use*; D004110:Diltiazem / Q000008:administration & dosage / Q000627:therapeutic use*; D004562:Electrocardiography; D006321:Heart / Q000187:drug effects / Q000502:physiology; D007274:Injections, Intraperitoneal; D008133:Long QT Syndrome / Q000139:chemically induced / Q000517:prevention & control*; D008297:Male; D008790:Metoprolol / Q000008:administration & dosage / Q000627:therapeutic use*; D010879:Piperazines / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors*; D011897:Random Allocation; D017207:Rats, Sprague-Dawley; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000037:antagonists & inhibitors; D013844:Thiazoles / Q000008:administration & dosage / Q000009:adverse effects / Q000037:antagonists & inhibitors*
chemical_list: D058671:Adrenergic beta-1 Receptor Antagonists; D000889:Anti-Arrhythmia Agents; D014150:Antipsychotic Agents; D002121:Calcium Channel Blockers; D004110:Diltiazem; D008790:Metoprolol; D010879:Piperazines; D017367:Selective Serotonin Reuptake Inhibitors; D013844:Thiazoles; C092292:ziprasidone
keywords: Ziprasidone; diltiazem; electrocardiogram; metoprolol; prolonged QT interval